In November of 2014, Orthopeutics launched a new entity responsible for all non-spine, human research, development, and commercialization built upon Orthopeutics’ core technologies.  Crosscoat Medical is currently raising grant (SBIR Phase II) and investment funding to develop and commercialize revolutionary micro-invasive and device coating delivered tissue modification treatments.  Orthopeutics new mission will be limited to intellectual property growth and management.